Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models
Biology of Reproduction · 2026
DOI: 10.1093/biolre/ioag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Reproduction, 2026. Verfasst von Chuyu Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Mifepristone, Adenomyosis, Prolactin, CA-125 Antigen. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Guangxi Natural Science Foundation Project.
Abstract (Originalsprache)
Uterine adenomyosis is a widespread condition that impairs female fertility, with elevated serum levels of cancer antigen 125 (CA125) and prolactin (PRL) often observed in affected women. Mifepristone has been investigated as a potential therapeutic agent to improve pregnancy outcomes in uterine adenomyosis patients. This study aimed to examine the effects of mifepristone on serum CA125 and PRL levels in uterine adenomyosis mouse models. The Institute of Cancer Research (ICR) mice were treated with varying doses of mifepristone after uterine adenomyosis was induced. Immunohistochemistry was used to analyze estrogen receptor and CA125 expression in uterine tissues, while serum CA125 and PRL levels were measured by enzyme-linked immunosorbent assay (ELISA). The study found that mifepristone treatment significantly reduced serum CA125 and PRL levels, and the 20 mg/kg/day dose was most effective in improving pregnancy outcomes. These findings suggest that mifepristone can reduce key biomarkers associated with uterine adenomyosis and improve fertility outcomes, offering a promising treatment option for women suffering from this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Pathology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Changsha, China.
ORCID-Profile: Bo Liu
Förderung
- Guangxi Natural Science Foundation Project
Zitieren
APA
Peng, C., Zeng, Y., Zhao, L., Gao, Z., Luo, L., Ou, S., Huang, Y., & Liu, B. (2026). Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models. Biology of Reproduction. https://doi.org/10.1093/biolre/ioag017
Vancouver
Peng C, Zeng Y, Zhao L, Gao Z, Luo L, Ou S, et al. Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models. Biology of Reproduction. 2026. doi:10.1093/biolre/ioag017
BibTeX
@article{Peng2026,
author = {Peng, Chuyu and Zeng, Yan and Zhao, Ling and Gao, Zhenqin and Luo, Liumei and Ou, Shanshan and Huang, Yingdan and Liu, Bo},
title = {Mifepristone reduces serum cancer antigen 125 and prolactin levels to improve pregnancy rates in uterine adenomyosis mouse models},
journal = {Biology of Reproduction},
year = {2026},
doi = {10.1093/biolre/ioag017}
}
EUVIMED